In biodistribution studies, uptake in MKN-45 (human gastric carcinoma with high c-MET expression) tumors of 76Br-onartuzumab was about 2-fold higher than in U87-MG tumors (moderate level c-MET expression). This evidence concerns the gene MET and gastric carcinoma.